HOME >> MEDICINE >> NEWS
Zengen reports positive phase I/II trial results of its peptide molecule for vaginal yeast infection

(May 25, 2004) Zengen Inc. announced today positive phase I/II results for its proprietary molecule CZEN-002 for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection. The open label, non-randomized study was designed to evaluate the safety, tolerability and pharmacokinetics of CZEN-002 in patients with VVC.

The majority of subjects in the study reported evidence of efficacy as determined by potassium hydroxide (KOH) tests and mycological cultures - 88.2 percent and 87.5 percent, respectively. A total of 20 female patients with VVC were enrolled and treated in the trial, and 17 completed the study. KOH testing and mycological cultures indicated that CZEN-002 is active and that five days of treatment provided positive evidence of anti-infective efficacy. CZEN-002 appeared safe and well-tolerated with no severe adverse reactions. In 100 percent of the plasma samples evaluated, concentrations of CZEN 002 were either not detected or were below the limit of quantitation.

"This trial clearly established the efficacy of CZEN-002," said William Smith, M.D., F.A.C.C., lead study investigator and associate professor, clinical medicine, at Tulane University School of Medicine and Louisiana State University Medical Center. "The encouraging results provide hope that this compound may become a new treatment option for the millions of women diagnosed each year with VVC."

The primary objective of the study was to evaluate the safety and tolerability of vaginally administered CZEN-002. A secondary objective was to assess the systemic absorption of CZEN-002 as determined by the plasma concentrations of the molecule through 21 days following dosing. The CZEN 002 was delivered to the 20 patients in a vaginal gel specifically designed for the purpose of the study.

"This clinical trial marks a major milestone for Zengen," said James M. Lipton, Ph.D., chief scientific officer of Zengen. "Our peptide appears to
'"/>

Contact: Cattaliya Snider
sniderc@ruderfinn.com
310-479-9929
Zengen
25-May-2004


Page: 1 2 3

Related medicine news :

1. Zengens new study reviews novel approach to control inflammation using melanocortin receptors
2. Lead in the environment causes violent crime, reports University of Pittsburgh researcher at AAAS
3. Study reports women dont experience undue pain, anxiety during mammography screening
4. Risks from labor after prior cesarean delivery low, study reports
5. Federal forum reports Americans aging well, but gaps remain
6. Early reports of thrombosis after insertion of drug-eluting stents
7. Study reports genetic susceptibility to alcoholism in NMDA receptor
8. Parents can provide accurate reports of their childrens ADHD symptoms
9. UCI Tobacco research center reports why teens are most vulnerable to smoking addiction
10. MIT reports new insights in visual recognition
11. Study reports improved method to identify fetal DNA in maternal blood samples

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2017)... ... 19, 2017 , ... "At your fingertips" electronic access to ... the Delaware Health Information Network (DHIN) have partnered to improve connectivity of this ... information exchange, DHIN stores and shares real-time health data for more than 2 ...
(Date:2/18/2017)... ... February 17, 2017 , ... CONTACT:, Glenn Vallecillos, MD, ... plastic surgeon Dr. Glenn Vallecillos experiments SculpSure, the hot, new, aesthetic, ... surgery has been centered around that idea that to achieve ones desired results ...
(Date:2/17/2017)... ... February 17, 2017 , ... While EHR data has ... introduced an innovative workstation designed to reduce nursing fatigue while enhancing productivity. Based ... Workstation offers a lightweight, highly mobile, multi-functional alternative to the limitations of handheld ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's mental functions, ... each and every seminar, session and class she offers. At the International ... which help energize creativity, focus mental functions, enhance athletic focus and skill sets, ...
(Date:2/17/2017)... ... February 17, 2017 , ... MAP Revenue Cycle Solutions ... Pilley has been promoted to Chief Executive Officer. , The need for ... a shift that demands the transition from pay-for-service to pay-for-performance models. By delivering ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Conn. , Feb. 17, 2017 Arvinas ... of drugs based on protein degradation, today announced the ... receptor (AR) PROTAC during a poster session at the ... (ASCO GU) in Orlando, FL. ... to validate our platform and the potential of PROTACs ...
(Date:2/17/2017)... YORK , Feb. 17, 2017   Risperdal ... side effects allegedly associated with use of the atypical ... Philadelphia Court of Common Pleas, where ... mass tort program. According to a notice posted on ... to convene a meeting on March 9, 2017 at ...
(Date:2/17/2017)... 17, 2017 On Thursday, February ... edged lower at the closing bell, while the Dow ... 20,000 benchmark. Moreover, five out of nine sectors ended ... yesterday,s market sentiment, Stock-Callers.com assessed the following Medical Appliances ... (NYSE: SNN ), ABIOMED Inc. (NASDAQ: ...
Breaking Medicine Technology:
Cached News: